ArticleAntimicrobial agents and chemotherapy2015
In Vitro Antimicrobial Susceptibility Patterns of Blastocystis.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- A Systematic Review about the Efficacy of Antiparasitic Agents in the Treatment of Blastocystis Species.Acta parasitologica · 2025Pooled it
- Evaluating the effects of metronidazole, metformin, and onion extract on GAPDH activity and nitric oxide production in Blastocystis sp. cultures: a biochemical and therapeutic approach.BMC complementary medicine and therapies · 2026Article
- Genetic diversity and zoonotic transmission potential ofParasite epidemiology and control · 2026Review
- Interpreting probiotic and combination-therapy studies in Blastocystis.Gut pathogens · 2026Article
- Association of Blastocystis species subtypes 3 and 4 with intestinal inflammation and response to metronidazole in symptomatic patients.BMC infectious diseases · 2026Article
- Prevalence and Subtypes of Blastocystis in Symptomatic Children in Egypt and Anti-Blastocystis Efficacy of Artemisia alba-Loaded Silver Nanoparticles In Vitro and in Swiss Albino Mice.Acta parasitologica · 2026Article
- Lactobacillus probiotics potential in Blastocystis infection: in vitro and in vivo studies.Gut pathogens · 2025Article
- Commensal, pathogen, or passenger? Rethinking the role ofOne health (Amsterdam, Netherlands) · 2025Review
- The effects of LED Spectra on synthesis of antiparasitic bioactive compound in Eurycoma longifolia hairy root culture against Blastocystis Sp.Scientific reports · 2025Article
- The Role ofPathogens (Basel, Switzerland) · 2025Review
- Atypical Presentation ofInternational medical case reports journal · 2025Article
- Resistance of Blastocystis to chlorine and hydrogen peroxide.Parasitology research · 2023Article
- Higher amoebic and metronidazole resistant forms of Blastocystis sp. seen in schizophrenic patients.Parasites & vectors · 2022Article
- In vitro susceptibility of humanSaudi journal of biological sciences · 2021Article
- Acute gastroenteritis due toBMJ case reports · 2020Article
- Evaluation of the effect of 1,3-bis-(4-phenyl-[1,2,3] triazole-1-il)2-propanol in comparison with metronidazole in an in vitro culture ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blastocystis is the most common human enteric protist with controversial clinical significance. Metronidazole is considered a first-line treatment for Blastocystis infection; however, there has been increasing evidence for the lack of efficacy of this treatment. Treatment failure has been reported in several clinical cases, and recent in vitro studies have suggested the occurrence of metronidazole-resistant strains. In this study, we tested 12 Blastocystis isolates from 4 common Blastocystis subtypes (ST1, ST3, ST4, and ST8) against 12 commonly used antimicrobials (metronidazole, paromomycin, ornidazole, albendazole, ivermectin, trimethoprim-sulfamethoxazole [TMP-SMX], furazolidone, nitazoxanide, secnidazole, fluconazole, nystatin, and itraconazole) at 10 different concentrations in vitro. It was found that each subtype showed little sensitivity to the commonly used metronidazole, paromomycin, and triple therapy (furazolidone, nitazoxanide, and secnidazole). This study highlights the efficacy of other potential drug treatments, including trimethoprim-sulfamethoxazole and ivermectin, and suggests that current treatment regimens be revised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.